Introduction
Tixagevimab/Cilgavimab, coronavirus infection
CORONAVIRUS INFECTION
Vaccination against the new coronavirus infection COVID-19 has reduced morbidity, mortality and the burden on the healthcare system worldwide (We have observed a revolution in the treatment of coronavirus infection and development of passive immunity against it. Nowadays several SARS-CoV-2-specific neutralizing mAbs in use possess not only a direct antiviral effect, but also the capability for prolonged circulation underpinning their protective potential (SARS-CoV-2 actively acquires new mutations leading to the appearance of numerous new SARS-CoV-2 variants (The mAbs have demonstrated efficacy and safety in many COVID-19 clinical trials around the world (Tixagevimab/Cilgavimab was one of the first mAbs registered worldwide for COVID-19 treatment, including the Russian Federation (Due to the generalized spread of different SARS-CoV-2 Omicron sublineages, we conducted a study of the effectiveness of virus-neutralizing monoclonal antibodies (Tixagevimab/Cilgavimab [Evusheld] and Regdanvimab [Regkiron]) for the treatment of the new coronavirus infection (COVID-19) in adult patients.